trial

A Study of ALKS 3831 in Adults With Schizophrenia

NCTId NCT01903837
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 347 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2014-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
347 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-06
Primary completion
2014-12
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Samidorphan (Low Dose)Samidorphan (Medium Dose)Samidorphan (High Dose)Olanzapine

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
Bernard L. Silverman, MDStudy Director

Sites

61 total
Little Rock, United StatesAnaheim, United StatesCosta Mesa, United StatesCulver City, United StatesEscondido, United StatesGarden Grove, United StatesNational City, United StatesOakland, United StatesOceanside, United StatesOrange, United StatesPico Rivera, United StatesSan Diego, United States

Linked catalysts

1
A Study of ALKS 3831 in Adults With Schizophrenia — primary completion2014-12

Facts & assertions

4 sourced
Enrollment
347
Phase
PHASE2
Primary Completion Date
2014-12
Status
COMPLETED
relationships
The graph out of here
drug
Samidorphan (Low Dose)
drug
Samidorphan (Medium Dose)
drug
Samidorphan (High Dose)
drug
Olanzapine
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Bernard L. Silverman, MD
person